

# Bristi Basu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4101283/publications.pdf>

Version: 2024-02-01

87  
papers

2,169  
citations

257450

24  
h-index

254184

43  
g-index

93  
all docs

93  
docs citations

93  
times ranked

3800  
citing authors

#	ARTICLE	IF	CITATIONS
1	Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 475-485.	2.5	13
2	Early derangement of INR predicts liver failure after liver resection for hepatocellular carcinoma. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2022, , .	1.8	3
3	TARGET National: A U.K.-wide liquid-based molecular profiling program to enhance recruitment to early-phase trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS3163-TPS3163.	1.6	2
4	Imaging Glioblastoma Metabolism by Using Hyperpolarized [ <sup>13</sup> C]Pyruvate Demonstrates Heterogeneity in Lactate Labeling: A Proof of Principle Study. <i>Radiology Imaging Cancer</i> , 2022, 4, .	1.6	17
5	LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumorsâ€”Results from the gastric cancer cohort.. <i>Journal of Clinical Oncology</i> , 2021, 39, 230-230.	1.6	8
6	LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumorsâ€”Results from the colorectal cancer cohort.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3564-3564.	1.6	8
7	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021, 3, 100260.	4.9	36
8	Upregulation of C/EBPÎ± Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5961-5978.	7.0	47
9	A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1009-1016.	7.0	56
10	Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. <i>Nature Communications</i> , 2020, 11, 4841.	12.8	129
11	Hyperpolarized <sup>13</sup> C MRI of Tumor Metabolism Demonstrates Early Metabolic Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Radiology Imaging Cancer</i> , 2020, 2, e200017.	1.6	40
12	Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 570958.	2.8	8
13	Intermittent schedules of the oral RAFâ€”MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. <i>Lancet Oncology</i> , The, 2020, 21, 1478-1488.	10.7	41
14	CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28960-28970.	7.1	150
15	MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBPÎ±, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. <i>Clinical Cancer Research</i> , 2020, 26, 3936-3946.	7.0	86
16	The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma â€” a substudy of the SORAMIC trial. <i>Acta Oncologica</i> , 2020, 59, 1028-1035.	1.8	11
17	Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers. <i>Cancer Discovery</i> , 2020, 10, 1528-1543.	9.4	82
18	Imaging breast cancer using hyperpolarized carbon-13 MRI. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 2092-2098.	7.1	138

#	ARTICLE	IF	CITATIONS
19	Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. <i>British Journal of Cancer</i> , 2020, 122, 1760-1768.	6.4	14
20	Detection limit of 89Zr-labeled T cells for cellular tracking: an in vitro imaging approach using clinical PET/CT and PET/MRI. <i>EJNMMI Research</i> , 2020, 10, 82.	2.5	9
21	Real-world experience of regorafenib in patients with hepatocellular carcinoma: A multicenter United Kingdom study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 499-499.	1.6	1
22	First-in-human phase I trial of small activating RNA (saRNA) oligonucleotide MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 554-554.	1.6	1
23	Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4601-4601.	1.6	1
24	A phase I trial a FR alpha targeted thymidylate synthase inhibitor CT900 exploring four schedules of treatment in expansion cohorts of patients with high-grade serous ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6043-6043.	1.6	1
25	First-in-human, first-in-class phase I study of MTL-CEBPA, a RNA oligonucleotide targeting the myeloid cell master regulator C/EBP $\beta$ , in patients with advanced hepatocellular cancer (HCC). <i>Annals of Oncology</i> , 2019, 30, v168-v169.	1.2	3
26	STAR-PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer. <i>Annals of Oncology</i> , 2019, 30, v267.	1.2	2
27	Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial. <i>Journal of Translational Medicine</i> , 2019, 17, 328.	4.4	51
28	Quantifying normal human brain metabolism using hyperpolarized [ $^{13}\text{C}$ ]pyruvate and magnetic resonance imaging. <i>NeuroImage</i> , 2019, 189, 171-179.	4.2	144
29	A phase I trial of the $\beta$ -secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. <i>British Journal of Cancer</i> , 2018, 118, 793-801.	6.4	90
30	Drug development and clinical trial design in pancreatico-biliary malignancies. <i>Current Problems in Cancer</i> , 2018, 42, 73-94.	2.0	5
31	Hyperpolarized carbon-13 magnetic resonance spectroscopic imaging: a clinical tool for studying tumour metabolism. <i>British Journal of Radiology</i> , 2018, 91, 20170688.	2.2	20
32	Early derangement of the international normalized ratio (INR) predicts liver insufficiency following liver resection for hepatocellular carcinoma. <i>Hpb</i> , 2018, 20, S396-S397.	0.3	0
33	Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 1918-1925.	1.2	26
34	Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP $\beta$ in patients with advanced liver cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2509-2509.	1.6	6
35	P3.02c-003 TAX-TORC: The Novel Combination of Weekly Paclitaxel and the Dual mTORC1/2 Inhibitor AZD2014 for the Treatment of Squamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1272-S1273.	1.1	3
36	Development of a Prognostic Model That Predicts Survival After Pancreaticoduodenectomy for Ampullary Cancer. <i>Pancreas</i> , 2017, 46, 1314-1321.	1.1	13

#	ARTICLE	IF	CITATIONS
37	Development of a prognostic model that predicts survival following Whipple's resection for ampullary adenocarcinoma.. Pancreatology, 2017, 17, S118.	1.1	0
38	Early Phase Clinical Trial Designs – State of Play and Adapting for the Future. Clinical Oncology, 2017, 29, 770-777.	1.4	24
39	Strong tumour cytidine deaminase (CDA) staining predicts for improved survival associated with sequential nab-Paclitaxel (nabP) and gemcitabine (GEM) chemotherapy as first line treatment of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC). Annals of Oncology, 2017, 28, v251-v252.	1.2	3
40	An investigator-initiated phase I study of ONX-0801, a first-in-class alpha folate receptor targeted, small molecule thymidylate synthase inhibitor in solid tumors.. Journal of Clinical Oncology, 2017, 35, 2503-2503.	1.6	12
41	A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (mPDAC).. Journal of Clinical Oncology, 2017, 35, 4100-4100.	1.6	2
42	First-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP- $\beta$ in patients with advanced liver cancer.. Journal of Clinical Oncology, 2017, 35, TPS2612-TPS2612.	1.6	2
43	A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2017, 35, 342-342.	1.6	1
44	TAX-TORC: A phase I trial of vistusertib (AZD2014) in combination with weekly paclitaxel with integrated pharmacodynamic (PD) and molecular characterization (MC) studies.. Journal of Clinical Oncology, 2017, 35, 2571-2571.	1.6	0
45	Intensive cisplatin/oral etoposide for epithelial ovarian cancer. Anti-Cancer Drugs, 2016, 27, 239-244.	1.4	2
46	Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 298-306.	8.1	114
47	PISARRO: A EUTROC phase 1b study of APR-246 with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC). Annals of Oncology, 2016, 27, vi123.	1.2	6
48	TAX-TORC: An investigator initiated phase I study combining the dual mTORC1/2 inhibitor AZD2014 in combination with weekly paclitaxel in high-grade serous ovarian cancer. Annals of Oncology, 2016, 27, vi115.	1.2	1
49	Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations. Cancer Research, 2016, 76, CT010-CT010.	0.9	11
50	Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGL-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.. Journal of Clinical Oncology, 2016, 34, 5547-5547.	1.6	7
51	PISARRO: A EUTROC phase 1b study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC).. Journal of Clinical Oncology, 2016, 34, 5571-5571.	1.6	14
52	CALIBRATE: Intensive profiling of circulating tumour DNA (ctDNA) from patients participating in experimental therapeutics trials including mutational profiles and copy number changes.. Journal of Clinical Oncology, 2016, 34, 11530-11530.	1.6	0
53	Abstract B40: Evaluation of the combination of AZD2014 and olaparib in pancreatic cancer cells. , 2016, , ,		0
54	Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience. Oncology, 2015, 89, 281-287.	1.9	41

#	ARTICLE	IF	CITATIONS
55	Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 977-984.	2.5	14
56	First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. <i>Clinical Cancer Research</i> , 2015, 21, 3412-3419.	7.0	101
57	EUTROC PiSARRO: A phase Ib study combining APR-246 with standard chemotherapy in platinum sensitive relapsed high grade serous ovarian carcinoma (HGSOc).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS5605-TPS5605.	1.6	5
58	Abstract CT138: Translating preclinical observations to the clinic: Combination of the dual m-TORC1/2 inhibitor AZD2014 and paclitaxel in ovarian and lung cancer. , 2015, , .		1
59	Abstract CT204: Preliminary results from PiSARRO, a phase Ib/II study of APR-246, a mutant p53 reactivating small molecule, in combination with standard chemotherapy in platinum-sensitive ovarian cancer. , 2015, , .		1
60	Phase I Multicentre Tax-Torc Trial of the Dual Mtorc1/2 Inhibitor Azd2014 (A) Plus Weekly Paclitaxel (P) in Patients (Pts) with Solid Tumours (Crukd/12/013). <i>Annals of Oncology</i> , 2014, 25, iv156.	1.2	1
61	Scheduling Nab-Paclitaxel with Gemcitabine (Siege): Randomised Phase II Trial to Investigate Two Different Schedules of Nab-Paclitaxel (Abx) Combined with Gemcitabine (Gem) As First Line Treatment for Metastatic Pancreatic Adenocarcinoma (PdAc). <i>Annals of Oncology</i> , 2014, 25, iv252.	1.2	1
62	Antiangiogenesis in Cancer Therapy. , 2014, , .		0
63	TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2607-2607.	1.6	2
64	A phase I trial of the ÉÉ-secretase inhibitor (GSI) MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4116-4116.	1.6	5
65	First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2580-2580.	1.6	50
66	Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials. <i>Oncology</i> , 2012, 83, 177-182.	1.9	1
67	Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience. <i>Clinical Cancer Research</i> , 2012, 18, 3750-3761.	7.0	65
68	Targeting the DNA damage response in oncology. <i>Current Opinion in Oncology</i> , 2012, 24, 316-324.	2.4	52
69	Progress in pancreatic cancer: moving beyond gemcitabine?. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 997-1000.	2.4	1
70	Association of creatine kinase and skin toxicity in phase I trials of anticancer agents. <i>British Journal of Cancer</i> , 2012, 107, 1797-1800.	6.4	15
71	Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain. <i>International Journal of Biochemistry and Cell Biology</i> , 2012, 44, 393-403.	2.8	38
72	PARP Inhibitors. <i>Drugs</i> , 2012, 72, 1579-1590.	10.9	36

#	ARTICLE	IF	CITATIONS
73	The Role of Angiogenesis Inhibitors in the Management of Melanoma. Current Topics in Medicinal Chemistry, 2012, 12, 32-49.	2.1	19
74	First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors.. Journal of Clinical Oncology, 2012, 30, 3004-3004.	1.6	21
75	1232 POSTER Creatinine Clearance (CrCl) as a Predictive Marker for the Risk of Toxicity From Molecularly Targeted Agents (MTA) in Phase I Trials. European Journal of Cancer, 2011, 47, S154.	2.8	0
76	1248 POSTER A Phase I Study Evaluating GDC-0941, a Pan-phosphoinositide-3 Kinase (PI3K) Inhibitor, in Patients (pts) With Advanced Solid Tumours, Multiple Myeloma, and PIK3Ca Mutant (mt) Tumours. European Journal of Cancer, 2011, 47, S159.	2.8	3
77	Targeting IGF-1R: throwing out the baby with the bathwater?. British Journal of Cancer, 2011, 104, 1-3.	6.4	26
78	Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptorâ€ (ER) or androgen receptor (AR) â€ positive advanced breast carcinoma resistant to standard endocrine therapies.. Journal of Clinical Oncology, 2011, 29, 2525-2525.	1.6	4
79	A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.. Journal of Clinical Oncology, 2011, 29, 3021-3021.	1.6	21
80	Perspectives in drug development for metastatic renal cell cancer. Targeted Oncology, 2010, 5, 139-156.	3.6	9
81	Targeting Insulin-Like Growth Factor Signaling: Rational Combination Strategies. Molecular Cancer Therapeutics, 2010, 9, 2447-2449.	4.1	20
82	Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin. Endocrine-Related Cancer, 2010, 17, R75-R90.	3.1	68
83	Targeting angiogenesis in melanoma: prospects for the future. Therapeutic Advances in Medical Oncology, 2010, 2, 367-380.	3.2	20
84	A phase 2 study of vatalanib in metastatic melanoma patients. European Journal of Cancer, 2010, 46, 2671-2673.	2.8	25
85	Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies. Expert Review of Anticancer Therapy, 2009, 9, 1583-1598.	2.4	26
86	A study to evaluate the use of CA125 in ovarian cancer follow-up: A change in practice led by patient preference. Gynecologic Oncology, 2006, 101, 4-11.	1.4	10
87	Systemic adjuvant therapies for breast cancer. , 2005, , 440-454.		0